Argenica Therapeutics Limited

ASX:AGN Voorraadrapport

Marktkapitalisatie: AU$92.9m

Argenica Therapeutics Beheer

Beheer criteriumcontroles 2/4

Momenteel beschikken wij niet over voldoende informatie over de CEO.

Belangrijke informatie

Liz Dallimore

Algemeen directeur

AU$424.2k

Totale compensatie

Percentage CEO-salaris67.8%
Dienstverband CEO2.6yrs
Eigendom CEO1.3%
Management gemiddelde ambtstermijngeen gegevens
Gemiddelde ambtstermijn bestuur1.6yrs

Recente managementupdates

Recent updates

Argenica Therapeutics (ASX:AGN) Is In A Good Position To Deliver On Growth Plans

Sep 23
Argenica Therapeutics (ASX:AGN) Is In A Good Position To Deliver On Growth Plans

Companies Like Argenica Therapeutics (ASX:AGN) Are In A Position To Invest In Growth

Jan 12
Companies Like Argenica Therapeutics (ASX:AGN) Are In A Position To Invest In Growth

Argenica Therapeutics (ASX:AGN) Is In A Strong Position To Grow Its Business

Jul 20
Argenica Therapeutics (ASX:AGN) Is In A Strong Position To Grow Its Business

Argenica Therapeutics (ASX:AGN) Is In A Strong Position To Grow Its Business

Apr 20
Argenica Therapeutics (ASX:AGN) Is In A Strong Position To Grow Its Business

We're Not Very Worried About Argenica Therapeutics' (ASX:AGN) Cash Burn Rate

Nov 30
We're Not Very Worried About Argenica Therapeutics' (ASX:AGN) Cash Burn Rate

Argenica Therapeutics (ASX:AGN) Is In A Good Position To Deliver On Growth Plans

Aug 12
Argenica Therapeutics (ASX:AGN) Is In A Good Position To Deliver On Growth Plans

Here's Why We're Not Too Worried About Argenica Therapeutics' (ASX:AGN) Cash Burn Situation

Apr 29
Here's Why We're Not Too Worried About Argenica Therapeutics' (ASX:AGN) Cash Burn Situation

Here's Why We're Not Too Worried About Argenica Therapeutics' (ASX:AGN) Cash Burn Situation

Dec 30
Here's Why We're Not Too Worried About Argenica Therapeutics' (ASX:AGN) Cash Burn Situation

We're Not Very Worried About Argenica Therapeutics' (ASX:AGN) Cash Burn Rate

Sep 16
We're Not Very Worried About Argenica Therapeutics' (ASX:AGN) Cash Burn Rate

Analyse CEO-vergoeding

Hoe is Liz Dallimore's beloning veranderd ten opzichte van Argenica Therapeutics's winst?
DatumTotale vergoedingSalarisBedrijfswinsten
Jun 30 2024AU$424kAU$288k

-AU$5m

Mar 31 2024n/an/a

-AU$5m

Dec 31 2023n/an/a

-AU$5m

Sep 30 2023n/an/a

-AU$5m

Jun 30 2023AU$675kAU$250k

-AU$5m

Mar 31 2023n/an/a

-AU$4m

Dec 31 2022n/an/a

-AU$4m

Sep 30 2022n/an/a

-AU$4m

Jun 30 2022AU$337kAU$228k

-AU$4m

Mar 31 2022n/an/a

-AU$3m

Dec 31 2021n/an/a

-AU$3m

Sep 30 2021n/an/a

-AU$2m

Jun 30 2021AU$145kAU$31k

-AU$1m

Compensatie versus markt: De totale vergoeding ($USD 276.54K ) Liz } is ongeveer het gemiddelde voor bedrijven van vergelijkbare omvang in de Australian markt ($USD 298.50K ).

Compensatie versus inkomsten: De vergoeding van Liz is het afgelopen jaar in lijn geweest met de bedrijfsprestaties.


CEO

Liz Dallimore

2.6yrs

Tenure

AU$424,246

Compensatie

Dr. Liz Dallimore (B. Sc. (Hons), MBA, PhD, GAICD) serves as Chief Executive Officer of Argenica Therapeutics Limited ands serves as its Managing Director and Director since April 4, 2022. She is a researc...


Bestuursleden

NaamPositieTenureCompensatieEigendom
Liz Dallimore
CEO, MD & Director2.6yrsAU$424.25k1.28%
A$ 1.2m
Dianne Angus
Independent Non-Executive Chairmanless than a yearAU$102.58kgeen gegevens
Geoffrey Donnan
Member of Clinical Advisory Committeeno datageen gegevensgeen gegevens
Terence Budge
Independent Non-Executive Director3.8yrsAU$44.40k0.63%
A$ 584.1k
Robert Black
Independent Non-Executive Directorless than a yeargeen gegevens0.020%
A$ 18.1k
Paul Bailey
Member of Clinical Advisory Committeeno datageen gegevensgeen gegevens
Tim Phillips
Member of Clinical Advisory Committeeno datageen gegevensgeen gegevens
David Blacker
Chairman of Clinical Advisory Committeeno datageen gegevensgeen gegevens
Jeffery Saver
Member of Clinical Advisory Committee2.3yrsgeen gegevensgeen gegevens
Mark Etherton
Independent Non-Executive Directorless than a yeargeen gegevensgeen gegevens

1.6yrs

Gemiddelde duur

Ervaren bestuur: De raad van bestuur van AGN wordt niet als ervaren beschouwd (gemiddelde ambtstermijn 1.6 jaar), wat duidt op een nieuw bestuur.